An exceptional effort to constitute a biobank of blood samples from patients with COVID-19, admitted to the hospital wards of the Public Hospitals in Paris (Assistance Publique-Hôpitaux de Paris: AP-HP), will be undertaken as an emergency measure, starting on March 23, 2020 with all regulatory and ethical authorizations already in place. The CIMI Research Centre proposes iCovid@APHP program that will rely on this longitudinal cohort, also open to other researchers and clinicians as per the decision of its Scientific Council and kept at the Biological Resource Centre of the Pitié Salpêtrière Hospital, to conduct its own translational research program with financial support from the Agence National de Recherche. Our goal is to rapidly carry out case-control studies on retrospectively defined patient groups, primarily in terms of resolution or fatal clinical evolution, and, using an “immunomics” approach, to rapidly define the kinetic parameters that characterize the different Covid-19 disease evolution profiles. The results from this basic research project will furthermore lead to the identification of biomarkers associated with disease severity and will make inroads to the development of new therapeutic targets.